CN112546067A - 针对自由基的稀土医药和保健品 - Google Patents
针对自由基的稀土医药和保健品 Download PDFInfo
- Publication number
- CN112546067A CN112546067A CN202011548484.5A CN202011548484A CN112546067A CN 112546067 A CN112546067 A CN 112546067A CN 202011548484 A CN202011548484 A CN 202011548484A CN 112546067 A CN112546067 A CN 112546067A
- Authority
- CN
- China
- Prior art keywords
- rare earth
- free radicals
- medicine
- health care
- care product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 42
- 150000002910 rare earth metals Chemical class 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229910052684 Cerium Inorganic materials 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 150000003254 radicals Chemical class 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 4
- 229910052779 Neodymium Inorganic materials 0.000 claims description 3
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229910052746 lanthanum Inorganic materials 0.000 claims description 3
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 3
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 3
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052706 scandium Inorganic materials 0.000 claims description 3
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- -1 rare earth inorganic Chemical class 0.000 claims description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 4
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 238000005502 peroxidation Methods 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000013613 poultry product Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了针对自由基的稀土医药和保健品，该类产品中均含有稀土元素化合物。本发明的药物和保健品含有的稀土元素，具有强大的抗氧化清除自由基的功能，其中以铈(Ce)最优。人体通过稀土保健品适量摄入稀土，可适时清除过量的自由基，防避机体器官受过氧化损伤，抗慢性氧化，延缓衰老。稀土药剂能抗炎救急，阻止或逆转消除重性炎症。
Description
技术领域
本发明涉及稀土医疗应用技术领域，尤其涉及针对自由基的稀土医药和保健品。
背景技术
稀土元素，在中国作为农作物肥料和畜禽饲料添加剂已有数十年，实践证明，稀土元素确有促进动植物生长和农牧产品增产的作用，并且食用有关农产品与畜禽产品也十分安全。尤其大量饲养业本身就是一个长期广泛的动物试验，充分证明了稀土元素确实具有有益于健康的生理活性。稀土毒理学研究已证明，稀土毒性与铁同级，与食盐相当。各项试验结果证明，稀土属于低毒或无毒类物质。已知稀土对人体健康的有益作用，适量摄入能增强机体活力，有益于各个器官，提高免疫力，抗炎抗老化，甚至有抑制癌变的作用。
发明内容
因此，基于以上背景，本发明提供了针对自由基的稀土医药和保健品，根据自由基学说，其能够调节人体自由基，达到治病与保健之目的。
本发明的技术方案为：
一类针对自由基的稀土医药和保健品，该类产品中均含有稀土元素化合物。
进一步地，所涉稀土元素限于镧(La)、铈(Ce)、镨(Pr)、钕(Nd)、钇(Y)、钪(Sc)共6个中的1个到6个。
进一步地，其剂型可为片剂或颗粒冲剂或注射剂。
进一步地，其可采用6个稀土元素中的1个到6个制成一元或多元稀土无机或有机化合物，其可以口服、注射、输液。
进一步地，用于口服治病和保健的剂型，所含稀土元素每人日摄入量，符合国家有关标准为原则，药品宜稍偏高，保健应偏低。
采用上述技术方案，具有的有益效果如下：
根据自由基学说，过量的自由基是人身机体的氧化剂，是万病之源，是导致衰老的元凶。因此，治病和保健都应该注重抗氧化，清除体内过量的自由基。而本发明的药物和保健品中含有的稀土元素，就具有强大的抗氧化清除自由基的功能，能抗炎，防避、阻止、消除炎症的重症病例，其中以铈最优。人体适量摄入稀土，能清除过量的有害自由基，避免器官组织细胞遭受过氧化损伤，还能提高免疫力，抗
老化，抑制癌变，达到治病保健双受益。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚，下面将结合本发明实施例，对本发明中的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1：一类针对自由基的稀土医药和保健品，该类产品中均含有稀土元素化合物。
产品中所含稀土元素有镧(La)、铈(Ce)、镨(pr)、钕(Nd)、钇(Y)、钪(Sc)共6个中的1个～6个，其剂型为针剂、片剂、颗粒冲剂，可以注射和口服。
其所含稀土元素每人日摄入限量以国家有关标准为准则，药品宜稍偏高，保健应偏低。
以上对本发明及其实施方式进行了描述，这种描述没有限制性，上述实施例中所示的也只是本发明的实施方式之一，实际的结构并不局限于此。总而言之如果本领域的普通技术人员受其启示，在不脱离本发明创造宗旨的情况下，不经创造性的设计出与该技术方案相似的结构方式及实施例，均应属于本发明的保护范围。
Claims (5)
1.一类针对自由基的稀土医药和保健品，其特征在于，该类产品中均含有稀土元素化合物。
2.根据权利要求1所述的含有稀土元素的内科药物和保健品，其特征在于，所述稀土元素为镧、铈、镨、钕、钇、钪共6个中的1个到6个。
3.根据权利要求1所述的针对自由基的稀土医药和保健品，其特征在于，其剂型可为片剂或颗粒冲剂或针注射剂。
4.根据权利要求1所述的针对自由基的稀土医药和保健品，其特征在于，其可采用6个稀土元素中的1个到6个制成一元或多元稀土无机或有机化合物，其可以口服、注射、输液。
5.根据权利要求1-4任一项所述的针对自由基的稀土医药和保健品，其特征在于，每人日摄入量以国家有关标准为准则，药品稍偏多，保健应偏少。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011548484.5A CN112546067A (zh) | 2020-12-24 | 2020-12-24 | 针对自由基的稀土医药和保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011548484.5A CN112546067A (zh) | 2020-12-24 | 2020-12-24 | 针对自由基的稀土医药和保健品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112546067A true CN112546067A (zh) | 2021-03-26 |
Family
ID=75033179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011548484.5A Pending CN112546067A (zh) | 2020-12-24 | 2020-12-24 | 针对自由基的稀土医药和保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112546067A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813701A (zh) * | 2005-02-05 | 2006-08-09 | 王飞欣 | 含有稀土元素非多糖化合物的药物、保健品、食品添加剂 |
| US20100098768A1 (en) * | 2008-10-16 | 2010-04-22 | Clarkson University | Method of neuroprotection from oxidant injury using metal oxide nanoparticles |
| CN102406663A (zh) * | 2011-02-25 | 2012-04-11 | 张锦仪 | 一种清除自由基的复合材料 |
-
2020
- 2020-12-24 CN CN202011548484.5A patent/CN112546067A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813701A (zh) * | 2005-02-05 | 2006-08-09 | 王飞欣 | 含有稀土元素非多糖化合物的药物、保健品、食品添加剂 |
| US20100098768A1 (en) * | 2008-10-16 | 2010-04-22 | Clarkson University | Method of neuroprotection from oxidant injury using metal oxide nanoparticles |
| CN102406663A (zh) * | 2011-02-25 | 2012-04-11 | 张锦仪 | 一种清除自由基的复合材料 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100363030C (zh) | 鱼、虾、蟹杀霉菌用中草药制剂 | |
| Yücel et al. | Effects of propolis administration on growth performance and neonatal diarrhea of calves | |
| CN112546067A (zh) | 针对自由基的稀土医药和保健品 | |
| KR101146645B1 (ko) | 가축사료 및 그 사료 제조방법 | |
| CN109224024A (zh) | 用于防治淡水鱼细菌混合感染的药物组合物及其应用方法 | |
| CN103393778B (zh) | 一种预防和治疗鱼类细菌和病毒性疾病的复方中草药制剂 | |
| CN103316094A (zh) | 一种增强免疫力的中兽药微粉剂及其制备方法 | |
| CN104825700A (zh) | 一种抗菌消炎的中药组合物 | |
| CN105560444B (zh) | 一种用于治疗牦牛胃肠炎的藏药组合物及其制备方法和应用 | |
| CN107823325A (zh) | 鱼类病菌抑制剂 | |
| CN101300984B (zh) | 一种多靶位生物制剂及其应用 | |
| CN102389030B (zh) | 枯草杆菌糖肽素168的用途 | |
| RU2464037C1 (ru) | Комбинированный метод лечения субклинического мастита у коров | |
| CN105395527A (zh) | 一种海洋生物护伤喷膜剂的制备方法 | |
| RU2005140156A (ru) | Применение аивлозина для лечения болезней, вызванных brachyspira pilosicoli или ornithobacterium rhinotracheale | |
| CN108815224A (zh) | 一种鲟鱼病菌抑制剂 | |
| CN106983771B (zh) | 防治海马头部溃烂病的药物及组合物 | |
| CN103272068B (zh) | 一种含替米考星的中西药复方制剂及其制备方法 | |
| CN102423007B (zh) | 防治稚鱼疾病的药饵 | |
| CN107714838A (zh) | 一种预防和治疗断奶仔猪腹泻的中药组合物及其应用 | |
| CN101990910A (zh) | 一种杀灭臭虫的喷雾剂 | |
| RU2388480C1 (ru) | Средство для предупреждения развития и лечения воспалительных процессов у животных | |
| Melnychuk | Therapeutical efficacy of medicaments on the basis of ivermectin at trichurosic invasion of pigs | |
| CN105030862B (zh) | 预防犊牛上呼吸道感染和腹泻的中药制剂及其使用方法 | |
| RU2356557C2 (ru) | Гомеопатическое средство для лечения и профилактики эндометрита животных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |